About:denisebell

Posts by denisebell :

President Biden Signs Flurry of Executive Orders on COVID-19, $15 Minimum Wage for Federal Workers, Buy American Next

Posted on by Denise Bell

Following his inauguration on January 20, President Biden signed 17 executive orders — including several aimed at COVID-19 and others overturning a number of President Trump’s previous executive orders and policies. The January 20 orders included a mask mandate for all federal properties and for interstate travel, rejoining the World Health Organization, reinstating the Global […]

Read More

Entrepreneur Your Startup – Get a Master’s Degree

Posted on by Denise Bell

Calling all life sciences early stage founders and startups! In partnership with the Lassonde Entrepreneur Institute at the University of Utah, the University’s David Eccles School of Business is now accepting applications to join its Master of Business Creation (MBC) program for 2021-2022. The priority application deadline is Feb. 12, 2021. This nine-month, professional-degree program […]

Read More

SDP Oncology Announces First Patient Dosed in Phase 1/2 Study of TP-0184 for the Treatment of Anemia in Patients with Low or Intermediate Risk Myelodysplastic Syndromes

Posted on by Denise Bell

  Lehi-based Sumitomo Dainippon Pharma Oncology (SDP Oncology) recently announced that the first patient has been dosed in a Phase 1/2 study evaluating the investigational agent TP-0184, an activin receptor-like kinase 2 (ALK2) and ALK5 inhibitor, for the treatment of anemia in adult patients with low or intermediate risk myelodysplastic syndromes (MDS). “The management of […]

Read More

PPP2 Loans Are Now Open

Posted on by Denise Bell

PPP loans have been reopened with an infusion of $284 billion for First Draw and Second Draw loans. First Draw loan applications will be accepted from January 11, 2021 to March 31, 2021. Second Draw applications begin January 13, 2021, until March 31, 2021. To promote access for smaller lenders and their customers, SBA will […]

Read More

Co-Diagnostics Anticipates Reporting Highest Quarterly Revenue Following Demand for COVID-19 Diagnostic Products

Posted on by Denise Bell

Based on its preliminary internal financial reporting for the fourth quarter 2020, Co-Diagnostics has announced that unaudited quarterly revenue for the company is anticipated to be the highest in the company’s history and to surpass analyst estimates. Analysts’ estimates for the fourth quarter ranged from $24 million to $25.98 million. Quarterly revenue is anticipated to […]

Read More

Clene Nanomedicine Closes Merger with Tottenham Acquisition I Limited;  Provides Corporate Update

Posted on by Denise Bell

Clene Nanomedicine, Inc. (Clene) last week announced the closing of a merger with Tottenham Acquisition I Limited (“Tottenham”) and provided a corporate update. Proceeds from this transaction totaled approximately $31.9 million. The combined, publicly traded company is operating under the name Clene Inc., and its common stock began trading on the NASDAQ Capital Market on […]

Read More

Early Risk Identification at Core of Innovative Kidney Care Partnership Between Renalytix, DaVita

Posted on by Denise Bell

Kidney care innovators Renalytix AI and DaVita are partnering on a new program aimed at slowing disease progression and improving health outcomes for the nation’s estimated 37 million adults with chronic kidney disease (CKD). This first of its kind program is expected to improve patient outcomes and provide meaningful cost reductions for healthcare providers and […]

Read More

Co-Diagnostics Designs Test to Detect Mutations for New Coronavirus Strain Using CoPrimer™ Platform

Posted on by Denise Bell

Co-Diagnostics has announced that it has completed principal design work for a PCR test that would allow researchers to identify certain mutations in a newly detected variant of SARS-CoV-2 known as VUI 202012/01. The new coronavirus strain comprises several mutations and may be more contagious than its predecessors. London and the southeast of Great Britain […]

Read More

Vertex Announces FDA Approvals for Expanded Use of Cystic Fibrosis Medicines 

Posted on by Denise Bell

Vertex has announced FDA approval of eligibility for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to include people with cystic fibrosis (CF) ages 12 years and older with certain mutations in the CFTR gene. SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) and KALYDECO® (ivacaftor) also received approvals to include additional responsive mutations in people with CF ages 6 years and older and age 4 […]

Read More

Phoenix PharmaLabs Announces New Investment Offering with Netcapital

Posted on by Denise Bell

Phoenix PharmaLabs (Phoenix), a Utah company developing potent, non-addictive treatments for pain and opioid and cocaine addictions, announced it has launched its second offering campaign on the Netcapital platform. This new offering follows a fund raise in 2019 of more than $1.1 million via Netcapital.  Proceeds from this latest campaign will further support the development […]

Read More

BioUtah Joins Patient Groups Opposing MFN

Posted on by Denise Bell

BioUtah joined numerous patient advocates and healthcare providers in sending a letter to U.S. House and Senate leaders in opposition to the Trump administration’s Most-Favored-Nation (MFN) drug pricing rule. The letter, organized by The Part B Access for Seniors and Physicians (ASP) Coalition, stated that the MFN model for Medicare Part B drugs will “lead […]

Read More